Aspen Pharmacare to Sell European Ovestin Rights to Ennogen for EUR 197 Million
Aspen Pharmacare will sell the European rights to Ovestin to Ennogen for EUR 197 million, plus EUR 4 million in inventory.
Related stories
CopperCorp sells Skyline to Bubalus; closing pending
CopperCorp has agreed to sell Skyline to Bubalus, but the transaction has not yet closed.
M impact | MNA | Nov 02, 2026, 11:04 AM UTC
Destination XL Group Temporarily Barred From Terminating Merger Agreement
Destination XL Group was temporarily enjoined from exercising its right to terminate its merger agreement with FBB Holdings.
M impact | MNA | Nov 02, 2026, 11:03 AM UTC
Public Policy Holding Deal Valued at Up to $80 Million
The deal includes $28 million initially and up to $52 million contingent.
M impact | MNA | Nov 02, 2026, 11:02 AM UTC
Public Policy Holding Agrees to Reevemark Consideration of Up to $80M
Public Policy Holding reported total consideration for Reevemark of up to $80 million.
M impact | MNA | Nov 02, 2026, 11:01 AM UTC
PPHC Announces Acquisition of Reevemark
M impact | MNA | Nov 02, 2026, 11:00 AM UTC
BMO Closes Acquisition of Euroz Hartleys' Australian Capital Markets Business
Bank of Montreal completed its acquisition of Euroz Hartleys' Australian capital markets business.
M impact | MNA | Nov 02, 2026, 10:59 AM UTC